News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hepatera Release: Maxwell Biotech Venture Fund’s Portfolio Company Hepatera Recruits First Patients in Phase 1b/2a Clinical Trial of Myrcludex B for HBV


12/12/2012 9:22:24 AM

MOSCOW--(BUSINESS WIRE)--Hepatera, a Russian biotech company and part of Maxwell Biotech Venture Fund’s portfolio, has announced today the inclusion of the first three patients with chronic hepatitis B in the clinical trial phase Ib-IIa of Myrcludex B. Hepatera was founded in 2011 and is focused on the development of innovative therapeutics for the treatment of liver diseases. The study is being conducted in major Russian specialized clinical centers and its results are expected in the end of 2013.

Read at BioSpace.com

Related News

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES